Clinical trials: Prostate Disease
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not…
- Trial name
- NCT03834493
- Testing
- Pembrolizumab, Enzalutamide
- Where
- 259 sites in United States, Argentina and 26 more
- Volunteers
- 1,244 people
- Sponsor
- Merck Sharp & Dohme LLC
Triple Negative Breast Cancer, HER2-negative Breast Cancer
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT06999187
- Testing
- DR-0202
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Dren Bio
Prostate Cancer
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
- Trial name
- NCT06462014
- Testing
- Relugolix
- Where
- United States
- Volunteers
- 507 people
- Sponsor
- Pfizer
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Safety and Effectiveness Study of the Zenflow Spring System
Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.
- Trial name
- BREEZE (NCT04987138)
- Testing
- Zenflow Spring System
- Where
- 7 sites in United States
- Volunteers
- 279 people
- Sponsor
- Zenflow, Inc.
Prostate Cancer
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
To assess the effects of i.v. zoledronic acid 4 mg with respect to safety and tolerability
- Trial name
- NCT00242554
- Testing
- Zoledronic acid
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Benign Prostatic Hyperplasia
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
This study is designed to compare safety and efficacy of monotherapy finasteride to combination therapy (finasteride and tamsulosin) in Asian men with benign prostatic hyperplasia (BPH) who are at least 50 years of age or older.
- Trial name
- NCT01534351
- Testing
- Finasteride, Tamsulosin
- Volunteers
- 1 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer of the Prostate, Neoplasms, Prostate
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
This study will be conducted in three parts. Part A is a dose-escalation study to determine two safe and tolerable doses of ASN001 for men with metastatic castration resistant prostate cancer.
- Conditions
- Cancer of the Prostate, Neoplasms, Prostate, Prostate Cancer, Prostatic Cancer
- Trial name
- NCT02349139
- Testing
- ASN001: Escalating dose Part A
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Asana BioSciences
Prostate Cancer, Non-small Cell Lung Cancer
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Primary Objectives: To characterize the safety and tolerability of isatuximab in combination with REGN2810 in participants with metastatic, castration-resistant prostate cancer (mCRPC) who were naïve to anti-programmed cell…
- Trial name
- NCT03367819
- Testing
- Isatuximab SAR650984, Cemiplimab REGN2810
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Sanofi
Benign Prostate Hyperplasia, Erectile Dysfunction
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of…
- Trial name
- NCT01937871
- Testing
- 5 mg Tadalafil, 0.2 mg Tamsulosin
- Where
- 14 sites in China
- Volunteers
- 909 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.
- Trial name
- NCT00316732
- Testing
- IPSS Questionnaire, EQ-5D Questionnaire
- Where
- 27 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- GlaxoSmithKline
Urinary Incontinence, Stress
Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate…
- Conditions
- Urinary Incontinence, Stress, Urination Disorders, Urologic Diseases
- Trial name
- NCT02291432
- Testing
- autologous muscle-derived cells (AMDC)
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cook MyoSite
Cancer, Solid Tumor Cancer
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies.
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate
- Trial name
- NCT07424547
- Testing
- SYS6043
- Where
- 5 sites in United States
- Volunteers
- 386 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Neoplasms, Prostate
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway…
- Trial name
- NCT07802704
- Testing
- Risvutatug rezetecan (Ris-Rez), Enzalutamide, Abiraterone
- Where
- 6 sites in Australia, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Open-Label, Randomised Parallel-Group Study
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.
- Trial name
- NCT00728533
- Testing
- Degarelix
- Sponsor
- Ferring Pharmaceuticals
Benign Prostatic Hyperplasia
Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia
To evaluate the efficacy and safety of the Water Vapor Thermal Therapy system for the treatment of Benign Prostatic Hyperplasia under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the…
- Trial name
- NCT06725212
- Testing
- Water Vapor Thermal Ablation, Cystoscopy
- Where
- 10 sites in China
- Volunteers
- 126 people
- Sponsor
- Medtecx Co Ltd.
Prostatic Hyperplasia
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects
The primary objective of this study is to determine the bioavailability of a FDC capsule formulation of dutasteride and tamsulosin hydrochloride (0.5 milligram [mg]/0.2 mg) relative to coadministration of one dutasteride 0.5 mg…
- Trial name
- NCT02509104
- Testing
- FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Prostate Cancer, Cancer of the PROSTATE
Urology of Virginia Case Series
The investigational protocol describes a small case series designed to compare three imaging modalities for use in visualizing prostate cancer.
- Conditions
- Prostate Cancer, Cancer of the PROSTATE, Prostatic Neoplasm
- Trial name
- NCT03035487
- Testing
- Ultrasound guided prostate exam using SOC ultrasound system, mpMRI guided prostate examination using PI-RADS v2, High-resolution micro-ultrasound guided prostate biopsy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Exact Imaging
Cancer
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of eFT508.
- Trial name
- NCT02605083
- Testing
- eFT508
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Effector Therapeutics
PET Imaging in Patients With Prostate Cancer
Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients
This study aims to evaluate the safety and pharmacokinetics of HRS-1738 injection in adult patients with prostate cancer.
- Trial name
- NCT07056439
- Testing
- HRS-1738 Injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.